Lonza reported a robust Q3 performance in its CDMO businesses, confirming an upgraded 2025 outlook with expected sales growth of 20% to 21% at constant exchange rates.

• Continuing strong demand in Integrated Biologics, with higher-than-expected contributions from the Vacaville facility.
• Confirmed expectations of organic sales growth in the Capsules and Health Ingredients business, transitioning from the post-pandemic destocking phase.
• Secured multiple significant contracts across various business platforms, indicating strong commercial momentum.
• Gradual recovery anticipated in the Cell & Gene sector, although operational performance remains below 2024 levels.
• Manufacturing footprint in the U.S. and Mexico strategically positioned to navigate geopolitical challenges, supporting growth and customer needs.